Clinical TrialsSearch results
Number of results: 537
Other
- A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancer
- Thymic cancer
- West Japan Oncology Group
- 2008-09-08
Other
- Lung Cancer Evaluation of TS-1 Study
- Previously untreated stageIIIB/IV NSCLC
- West Japan Oncology Group
- 2006-10-18
Other
- Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer
- Non-small cell lung cancer
- West Japan Oncology Group
- 2009-03-17
Other
- Phase II Study of Amrubicin in Patients with Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
- All patients had histologocally or cytologically confirmed locally advanced (non-irradiated) or metastatic NSCLC, with failure of platinum-based chemotherapy (exception for UFT and gefitinib).
- West Japan Oncology Group
- 2005-08-22
Other
- phase II study of gefitinib as a first-line therapy in elderly patients with lung adenocarcinoma.
- lung adenocarcinoma
- West Japan Oncology Group
- 2005-09-08
Other
- Phase III study of gefitinib versus erlotinib in patients with previously treated lung adeno carcinoma
- Previously treated lung adeno carcinoma
- West Japan Oncology Group
- 2009-06-19
Other
- PhaseIII study of gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer with EGFR mutation
- non small cell lung cancer
- West Japan Oncology Group
- 2006-12-11
Other
- Randomized phase III study of nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung
- squamous cell carcinoma of the lung
- West Japan Oncology Group
- 2009-06-30
Other
- Randomized phase III study of CPT-11 versus Weekly Paclitaxel for unresectable or recurrent gastric cancer refractory to combination chemotherapy with fluoropyrimidine plus platinum.
- unresectable or recurrent gastric cancer refractory to combination chemotherapy with fluoropyrimidine plus platinum
- West Japan Oncology Group
- 2008-07-15
Other
- Randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer
- metastatic colorectal cancer
- West Japan Oncology Group
- 2008-09-26